North America Vaccine Adjuvants Market

The North America vaccine adjuvants market was valued at US$ 1,044.84 million in 2022 and is expected to reach US$ 2,862.04 million by 2030; it is estimated to register a CAGR of 13.4% from 2022 to 2030.

Rising Number of Infectious Disease Outbreaks and Pandemic Fuels North America Vaccine Adjuvants Market

According to the World Bank 2023 report, bacterial, viral, parasite, or fungal diseases can be contagious, spreading directly from person to person or animal to person. As per the National Institute of Health (NIH) report, the H1N1 influenza pandemic resulted in losses of ~US$ 2.8 billion to the Mexican tourism industry, as the footfall of tourists decreased by nearly 1 million over a 5-month window of the contagious spread of H1N1 virus. The Mexican state of Texcoco reported an outbreak of low pathogenicity avian influenza (LPAI) A(H5N2) in March 2024, and Temascalapa municipality in the same state reported another outbreak in April. Additionally, in the state of Michoacán, a private poultry farm detected a high-pathogenicity avian influenza A(H5N2) outbreak that was discovered in March 2024. In 2022, it was reported that both LPAI and HPAI A(H5) subtypes have been found in bird species in Mexico, both recently and in the past. Although they typically infect animals, animal influenza viruses can also infect people. Human infections have mostly been contracted via close contact with animals that are infected or contaminated environments. Influenza A viruses can be categorized as avian influenza, swine influenza, or other animal influenza viruses based on their original host. Therefore, the emergence of various infectious diseases with the associated cost burden accelerates the manufacturers' demand for vaccines and vaccine adjuvants.

COVAXIN, a vaccine developed by Bharat Biotech to fight against the COVID-19 pandemic, uses Alhydroxiquim-II as an adjuvant. The biotech company ViroVax LLC discovered and tested this adjuvant in the laboratory. The pharmacological action of Alhydroxiquim-II is that it travels through lymph nodes and activates TLR7 and TLR8 cellular receptors, which play a vital role in the immune response against viruses. Alhydroxiquim-II is the first adjuvant responsible for activating TLR7 and TLR8, thus stimulating people’s immune responses. Therefore, the rising number of infectious disease outbreaks and pandemics, accounting for high healthcare costs, propels the demand for vaccine adjuvants.

North America Vaccine Adjuvants Market Overview

The North America vaccine adjuvants market has been segmented into the US, Canada, and Mexico. Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

North America Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

North America Vaccine Adjuvants Strategic Insights

Strategic insights for the North America Vaccine Adjuvants provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Vaccine Adjuvants Report Scope

North America Vaccine Adjuvants Regional Insights

The geographic scope of the North America Vaccine Adjuvants refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The North America vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the North America vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the North America vaccine adjuvants market share in 2022.

By type, the North America vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of North America vaccine adjuvants market in 2022.

By country, the North America vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; Dynavax Technologies Corp; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; Seppic SA; and SPI Pharma Inc are some of the leading companies operating in the North America vaccine adjuvants market.